PARAMUS, N.J., Aug. 30, 2021 /PRNewswire/ — Epygenix Therapeutics, Inc. («Epygenix»), a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S. Food and Drug Administration («FDA») has accepted the Company’s Investigational New Drug («IND») application to initiate A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome.
LGS is a rare epileptic encephalopathy presenting in childhood with intractable seizures. Approximately 48,000 children and adults in the United States currently suffer with LGS. Characterized by a triad of signs including multiple seizure types, slow spike-wave complexes on electroencephalographic (EEG) recordings, and impairment of cognitive function, therapeutic options for LGS are desperately needed as seizure control with currently available treatments is not adequate.
«We are very pleased with the FDA acceptance of our IND, because this is one of the significant development milestones for the Company to begin its expansion to other rare genetic epilepsies. We will explore the efficacy of EPX-100 as a novel treatment for those patients suffering with refractory epilepsies. Our team is now poised to proceed with a clinical study of EPX-100 in LGS patients,» says Dr. Hahn-Jun Lee, M.Sc., Ph.D., president and CEO of Epygenix Therapeutics, Inc.
Dr. Scott C. Baraban, Ph.D., Professor & William K. Bowes Jr. Endowed Chair in Neuroscience Research at UCSF and Chair of the Scientific Advisory Board at Epygenix Therapeutics, Inc. issued a joint comment that «With IND acceptance for LGS, we continue to be the leader in moving drug candidates discovered in preclinical zebrafish models quickly toward clinical trials. We are excited to now expand this approach to include those suffering with LGS.»
Alex Yang, J.D., LLM, President and CEO of Mstone Partners and Chair of the Board at Epygenix Therapeutics also stated that «Epygenix is committed to provide the best-in-class drug options by expanding indications that are safe, effective, and patient-friendly to cover a broad category of refractory genetic epilepsies. We are very excited to achieve another development milestone towards commercialization as we plan to expand further into other rare epileptic indications.»
About Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing drugs to treat rare and intractable genetic epilepsy. Epygenix is currently focused on developing EPX-100, -200, and -300. These candidates abolish convulsive behavior and electrographic seizure activity and were discovered in a zebrafish Dravet Syndrome model which mimics the human pathology and confirmed its validity by the human efficacy with EPX-200 and -300. For more information, please visit www.epygenix.com.
EPX-100 is a first-generation antihistamine which was safely used to treat itch between 1950 and 1970. EPX-100 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish models for Dravet Syndrome. EPX-100 antiepileptic action, however, is not through a histaminergic mechanism of action, but via modulation of serotonin (5HT) signaling pathways.
Hahn-Jun Lee, M.Sc., Ph.D.
View original content to download multimedia:https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-fda-acceptance-of-ind-to-initiate-a-clinical-trial-of-epx-100-to-treat-lennox-gastaut-syndrome-301364855.html
SOURCE Epygenix Therapeutics